Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 10/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR1E | P28566 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31703372 | 0.93 | TMEM97 (0.48) | TMEM97SIGMAR1HRH1HRH3HTR1A | |
| SCHEMBL23296608 | 0.91 | TMEM97 (0.47) | TMEM97SIGMAR1HRH1HRH3HTR1A | |
| SCHEMBL23296610 | 0.91 | TMEM97 (0.47) | TMEM97SIGMAR1HRH1HRH3HTR1A | |
| SCHEMBL31703435 | 0.85 | TMEM97 (0.49) | TMEM97SIGMAR1HRH1HRH3HTR1A | |
| SCHEMBL26985602 | 0.83 | TMEM97 (0.47) | TMEM97SIGMAR1HRH1HRH3HTR1A | |
| SCHEMBL31228353 | 0.83 | TMEM97 (0.47) | TMEM97SIGMAR1HRH1HRH3HTR1A | |
| SCHEMBL25889395 | 0.82 | NR1H2 (0.51) | TMEM97SIGMAR1HRH1HRH3HTR1A | |
| SCHEMBL25776878 | 0.81 | HDAC3 (0.51) | HDAC1HDAC3HDAC2HDAC6MEN1 | |
| SCHEMBL31133626 | 0.80 | TMEM97 (0.44) | TMEM97SIGMAR1HRH1HRH3HTR1A | |
| SCHEMBL31133683 | 0.78 | TMEM97 (0.42) | TMEM97SIGMAR1HRH1HRH3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | TMEM97 3611/4885SIGMAR1 4597/4885HRH1 2865/4885 |
| US-20230234929-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | TMEM97 3495/4885SIGMAR1 4606/4885HRH1 2949/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | TMEM97 2438/4885SIGMAR1 3617/4885HRH1 3515/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | TMEM97 3495/4885SIGMAR1 4606/4885HRH1 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.